Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors were recently reported to have cardioprotective effects via amelioration of ventricular function. However, the role of DPP-4 inhibition in atrial remodeling, especially of the arrhythmogenic substrate, remains unclear. We investigated the effects of a DPP-4 inhibitor, alogliptin, on atrial fibrillation (AF) in a rabbit model of heart failure caused by ventricular tachypacing (VTP). Rabbits subjected to VTP at 380 bpm for 1 or 3 weeks, with or without alogliptin treatment, were assessed using echocardiography, electrophysiology, histology, and immunoblotting and compared with nonpaced animals. VTP rabbits exhibited increased duration of atrial burst pacing-induced AF, whereas administration of alogliptin shortened this duration by 73%. The extent of atrial fibrosis after VTP was reduced by 39% in the alogliptin-treated group. VTP rabbits treated with alogliptin displayed a 1.6-fold increase in left atrial myocardial capillary density compared with nontreated rabbits. A 2-fold increase in endothelial nitric oxide synthase (eNOS) phosphorylation was observed in the left atrium of alogliptin-treated rabbits compared with nontreated rabbits. Moreover, a nitric oxide synthase inhibitor (N(ω)-...Continue Reading
References
Nov 1, 1985·Journal of the American College of Cardiology·J J Gallagher
Jul 7, 1999·Circulation·D LiS Nattel
Nov 21, 2001·Circulation·D LiS Nattel
Jun 5, 2002·Circulation·Kaori ShinagawaStanley Nattel
Jun 14, 2002·Cardiovascular Research·Maurits AllessieUlrich Schotten
Oct 9, 2002·Circulation·Yukiomi TsujiItsuo Kodama
May 29, 2003·Circulation·Thomas J WangEmelia J Benjamin
Jun 25, 2003·Journal of the American College of Cardiology·Koichiro KumagaiKeijiro Saku
Mar 17, 2004·Cardiovascular Research·Koichiro KumagaiKeijiro Saku
Jul 31, 2007·Nature Medicine·Elisabeth M ZeisbergRaghu Kalluri
Feb 26, 2008·Journal of the American College of Cardiology·Brett Burstein, Stanley Nattel
Mar 1, 2008·The American Journal of Cardiology·Tonje Amb AksnesStevo Julius
Mar 4, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Masayuki ShimanoToyoaki Murohara
Apr 15, 2008·Clinical Therapeutics·Ronald ChristopherAziz Karim
Jan 26, 2010·Diabetes·Meghan SauvéDaniel J Drucker
Mar 9, 2010·Journal of Molecular and Cellular Cardiology·Masayuki ShimanoKenneth Walsh
Nov 18, 2010·American Journal of Physiology. Endocrinology and Metabolism·A D DobrianJ L Nadler
Feb 22, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Kazuhisa KitamuraToyoaki Murohara
Mar 15, 2011·Vascular Pharmacology·Zubair ShahSanjay Rajagopalan
Oct 19, 2011·Circulation·Zubair ShahSanjay Rajagopalan
Mar 1, 2012·Circulation. Heart Failure·Stavros E MountantonakisGregg C Fonarow
Jul 14, 2012·British Journal of Pharmacology·Chun-Yao HuangFeng-Yen Lin
Oct 5, 2012·Circulation·Toshimasa ShigetaToyoaki Murohara
Jan 9, 2013·Biochemical Pharmacology·Sonia ZambranoCarmen M Vázquez
Jul 19, 2013·Cardiovascular Research·Andrey KazakovUlrich Laufs
Aug 8, 2014·The Journal of Biological Chemistry·Masakazu IshiiToyoaki Murohara
Citations
Jan 21, 2016·International Journal of Cardiology·Xiaowei ZhangTong Liu
Sep 30, 2015·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum
Dec 21, 2017·Cardiovascular Diabetology·Chia-Yu ChangLai-Chu See
Apr 28, 2018·Current Opinion in Cardiology·Kalliopi PafiliNikolaos Papanas
May 17, 2017·Journal of the American Heart Association·Xiaowei ZhangTong Liu
Dec 29, 2018·Cardiovascular Diabetology·Xiaowei ZhangTong Liu
Oct 1, 2017·Cardiovascular Diabetology·Basil S KaramFadi G Akar
Jan 21, 2020·Frontiers in Pharmacology·Raffaele CoppiniLaura Raimondi
Sep 22, 2019·Journal of Cardiac Failure·Milton Packer
Jun 3, 2021·Journal of Clinical Medicine·Paweł Muszyński, Tomasz A Bonda
Jun 12, 2021·Heart Rhythm O2·Hailey J JansenRobert A Rose